Physician profile
Steven Choi
NPI 1700085263
$4,144.09
in general payments reported to CMS, 2019-2025
42 companies · $3,013 in 2025
The $3,013 reported for 2025 was more than what 92% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $396 · 2022: $272 · 2023: $221 · 2024: $243 · 2025: $3,013.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,452 · Travel and Lodging: $24.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,452.28 |
| Travel and Lodging | $24.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $824.97 | 2021-2025 | Vraylar |
| Axsome Therapeutics, INC. | $390.43 | 2025 | Sunosi, Symbravo |
| Teva Pharmaceuticals USA, INC. | $332.28 | 2021-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Neurocrine Biosciences, INC. | $266.58 | 2021-2025 | Ingrezza |
| Emd Serono, INC. | $207.28 | 2025 | |
| Eisai INC. | $202.34 | 2025 | |
| Lundbeck LLC | $183.47 | 2024-2025 | Vyepti, Abilify Maintena |
| Amneal Pharmaceuticals LLC | $168.38 | 2025 | Crexont |
| Biogen, INC. | $160.49 | 2025 | Leqembi, Tysabri, Spinraza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $158.20 | 2021-2022 | |
| Harmony Biosciences LLC | $111.19 | 2025 | |
| Jazz Pharmaceuticals INC. | $91.39 | 2025 | |
| Lilly USA, LLC | $89.07 | 2025 | Amyvid, Kisunla, Zepbound |
| Janssen Pharmaceuticals, INC | $66.54 | 2022 | |
| Sunovion Pharmaceuticals INC. | $64.59 | 2021-2022 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $60.99 | 2025 | Sublocade |
| Pfizer INC. | $54.60 | 2025 | |
| Merz Pharmaceuticals, LLC | $51.13 | 2025 | Xeomin, Inbrija |
| Otsuka America Pharmaceutical, INC. | $51.10 | 2021-2025 | Rexulti |
| Tanabe Pharma America, INC. | $49.80 | 2025 | Radicava |
| Argenx US, INC. | $43.50 | 2025 | Vyvgart Hytrulo |
| Alkermes, INC. | $43.33 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $40.27 | 2021-2024 | Qelbree |
| Azurity Pharmaceuticals, INC. | $36.11 | 2025 | Horizant |
| Catalyst Pharmaceuticals, INC. | $32.76 | 2025 | |
| Boston Scientific Corporation | $29.11 | 2025 | Wavewriter Alpha Prime 16 |
| Electronic Waveform Lab, INC. | $28.67 | 2025 | |
| Neurelis, INC. | $25.87 | 2025 | Valtoco |
| Ironshore Pharmaceuticals INC. | $25.33 | 2021 | |
| Corium, LLC | $25.23 | 2023 | Azstarys |
| Vanda Pharmaceuticals INC. | $24.92 | 2025 | Ponvory |
| 3b Medical, INC. | $24.63 | 2025 | Luna |
| Noctrix Health, INC. | $24.60 | 2025 | Nidra |
| C2n Diagnostics, LLC | $22.63 | 2025 | Precivityad2 |
| Ucb, INC. | $21.56 | 2025 | Nayzilam |
| Grifols USA, LLC | $19.22 | 2025 | Gamunex-C |
| Collegium Pharmaceutical, INC. | $19.07 | 2025 | Belbuca |
| Bioxcel Therapeutics, INC. | $18.66 | 2024 | Igalmi |
| Takeda Pharmaceuticals U.S.A., INC. | $17.17 | 2025 | Hyqvia |
| Idorsia Pharmaceuticals US INC | $16.85 | 2025 | Quviviq |
| Avadel Cns Pharmaceuticals, LLC | $13.67 | 2025 | Lumryz |
| Neuronetics, INC. | $6.11 | 2025 | Neurostar Tms Therapy System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Choi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.